SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN

NCT02057107 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Previously-Irradiated
Squamous Cell Carcinoma of the Head and Neck Cancer

Interventions

RADIATION: SBRT
DRUG: Cetuximab
DRUG: Docetaxel

Sponsor

Heath Skinner